A study showing feasibility and preliminary efficacy of off-the-shelf CAR T cells represents steady progress on the long road to clinical use.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).
Martin, T. et al. J. Clin. Oncol. https://doi.org/10.1200/JCO.22.00842 (2022).
Delforge, M. et al. Blood Adv. 6, 1309–1318 (2022).
Mailankody, S. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02182-7 (2023).
Graham, C. E. et al. Leukemia 35, 3581–3584 (2021).
Goodman, A. Patients with multiple myeloma may face CAR T-cell shortages. ASCO Post (25 September 2022).
Benjamin, R. et al. Lancet Haematol 9, e833–e843 (2022).
Ottaviano, G. et al. Sci. Transl. Med. 14, eabq3010 (2022).
Berdeja, J. G. et al. Lancet 398, 314–324 (2021).
Lonial, S. et al. Cancer 127, 4198–4212 (2021).
Moreau, P. et al. N. Engl. J. Med. 387, 495–505 (2022).
Sommer, C. et al. Blood 136, 8 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.N.B. is on the scientific advisory board for Kyverna Therapeutics, Inc. (unpaid position). J.N.K. receives royalties from Kite (a Gilead company), Celgene/Bristol Myers Squibb and Kyverna Therapeutics, Inc.; and research funding from Kite and Celgene/Bristol Myers Squibb.
Rights and permissions
About this article
Cite this article
Brudno, J.N., Kochenderfer, J.N. Off-the-shelf CAR T cells for multiple myeloma. Nat Med 29, 303–304 (2023). https://doi.org/10.1038/s41591-022-02195-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02195-2